Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma

A small molecule which specifically blocks the interaction of Rictor and mTOR was identified utilizing a high-throughput yeast two-hybrid screen and evaluated as a potential inhibitor of mTORC2 activity in glioblastoma multiforme (GBM). In vitro, CID613034 inhibited mTORC2 kinase activity at submicromolar concentrations and in cellular assays specifically inhibited phosphorylation of mTORC2 substrates, including AKT (Ser-473), NDRG1 (Thr-346) and PKCα (Ser-657), while having no appreciable effects on the phosphorylation status of the mTORC1 substrate S6K (Thr-389) or mTORC1-dependent negative feedback loops. CID613034 demonstrated significant inhibitory effects on cell growth, motility and invasiveness in GBM cell lines and sensitivity correlated with relative Rictor or SIN1 expression. Structure-activity relationship analyses afforded an inhibitor, JR-AB2-011, with improved anti-GBM properties and blocked mTORC2 signaling and Rictor association with mTOR at lower effective concentrations. In GBM xenograft studies, JR-AB2-011 demonstrated significant anti-tumor properties. These data support mTORC2 as a viable therapeutic target in GBM and suggest that targeting protein-protein interactions critical for mTORC2 function is an effective strategy to achieve therapeutic responses.

[1]  D. Guertin,et al.  Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy , 2010, Oncogene.

[2]  A. Goffeau,et al.  The pleitropic drug ABC transporters from Saccharomyces cerevisiae. , 2001, Journal of molecular microbiology and biotechnology.

[3]  S. Gygi,et al.  Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction. , 2010, Molecular cell.

[4]  P. Mischel,et al.  mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment , 2015, Brain pathology.

[5]  J. Masri,et al.  Hsp70 associates with Rictor and is required for mTORC2 formation and activity. , 2008, Biochemical and biophysical research communications.

[6]  Suimin Qiu,et al.  Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer , 2009, Clinical Cancer Research.

[7]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[8]  Fei Zhang,et al.  mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis. , 2010, Cancer research.

[9]  R. Loewith,et al.  TORC2 Structure and Function. , 2016, Trends in biochemical sciences.

[10]  Nadine Cybulski,et al.  TOR complex 2: a signaling pathway of its own. , 2009, Trends in biochemical sciences.

[11]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[12]  F. Tamanoi,et al.  Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interaction. , 2006, Methods in enzymology.

[13]  R. Loewith,et al.  Molecular Organization of Target of Rapamycin Complex 2* , 2005, Journal of Biological Chemistry.

[14]  B. Holmes,et al.  Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma* , 2016, The Journal of Biological Chemistry.

[15]  R. Aebersold,et al.  Target of Rapamycin Complex 2 Regulates Actin Polarization and Endocytosis via Multiple Pathways* , 2015, The Journal of Biological Chemistry.

[16]  Jie Zhang,et al.  Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Sabatini,et al.  mTOR Mediated Anti-Cancer Drug Discovery. , 2009, Drug discovery today. Therapeutic strategies.

[18]  Manfred Westphal,et al.  The neurobiology of gliomas: from cell biology to the development of therapeutic approaches , 2011, Nature Reviews Neuroscience.

[19]  C. Jacq,et al.  Multiple-drug-resistance phenomenon in the yeast Saccharomyces cerevisiae: involvement of two hexose transporters , 1997, Molecular and cellular biology.

[20]  W. Weiss,et al.  Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. , 2010, Current topics in microbiology and immunology.

[21]  M. Hall,et al.  Activation of mTORC 2 by Association with the Ribosome , 2011 .

[22]  D. Sabatini,et al.  DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival , 2009, Cell.

[23]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[24]  X. Bai,et al.  Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin. , 2016, Current cancer drug targets.

[25]  J. Masri,et al.  Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma , 2011, Molecular Cancer Therapeutics.

[26]  T. Cloughesy,et al.  Emerging function of mTORC 2 as a core regulator in glioblastoma : metabolic reprogramming and drug resistance , 2015 .

[27]  Huajun Yan,et al.  Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade , 2005, Molecular Cancer Therapeutics.

[28]  Lynda Chin,et al.  Emerging insights into the molecular and cellular basis of glioblastoma. , 2012, Genes & development.

[29]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[30]  S. Dedhar,et al.  Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial–mesenchymal transition (EMT) , 2013, Oncogene.

[31]  Sanjay Goel,et al.  RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors. , 2015, Cancer discovery.

[32]  T. Cloughesy,et al.  New Strategies in the Molecular Targeting of Glioblastoma: How Do You Hit a Moving Target? , 2011, Clinical Cancer Research.

[33]  N. Krogan,et al.  Chemical genetics of rapamycin-insensitive TORC2 in S. cerevisiae. , 2013, Cell reports.

[34]  E. White,et al.  The Double-Edged Sword of Autophagy Modulation in Cancer , 2009, Clinical Cancer Research.

[35]  Webster K. Cavenee,et al.  Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance , 2015, Proceedings of the National Academy of Sciences.

[36]  T. Cloughesy,et al.  Glioblastoma: from molecular pathology to targeted treatment. , 2014, Annual review of pathology.

[37]  P. Wingfield.  Overview of the Purification of Recombinant Proteins , 2015, Current protocols in protein science.

[38]  J. Avruch,et al.  A Rictor-Myo 1 c Complex Participates in Dynamic Cortical Actin Events in 3 T 3L 1 Adipocytes ‡ , 2017 .

[39]  Joseph Gera,et al.  mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. , 2007, Cancer research.

[40]  A. Guha,et al.  Conditional Astroglial Rictor Overexpression Induces Malignant Glioma in Mice , 2012, PloS one.

[41]  Ivan Babic,et al.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. , 2011, Cancer discovery.